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144Growth factors and experimental arterial grafts
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Background: The production of growth factors from several experimental arterial conduits was determined.
Methods:We implanted 105 experimental arterial grafts that were 1 cm long in the abdominal aorta of Lewis rats (average
weight, 250 g). Five different types of grafts were analyzed: arterial isografts, vein grafts, arterial allografts, and poly-
tetrafluoroethylene (PTFE) grafts with normal or decreased compliance. Animals were killed humanely 4 weeks after
surgery and the production of platelet-derived growth factor (PDGF), basic fibroblast growth factor (bFGF), trans-
forming growth factor-b, tumor necrosis factor-a, and interleukin-1 was analyzed.
Results: Myointimal hyperplasia (MH) was evident in vein grafts, arterial allografts, and PTFE grafts, but not in arterial
isografts. Growth factor production was increased for grafts prone to develop MH like vein, PTFE grafts, and arterial
allografts. PDGF and bFGF were increased significantly for PTFE and vein grafts, but not for arterial allografts. The
importance of bFGF and PGDF was confirmed by the capability of antibody to PDGF and to bFGF to reduce the
mitogenic activity of smooth muscle cells, in vivo and in vitro, for PTFE and vein grafts, but not for arterial allografts, in
which a predominant role was played by interleukin-1 and tumor necrosis factor-a.
Conclusions: Agents able to neutralize this increased production of growth factors, either directly or by competition with
their receptors, can prevent MH formation. (J Vasc Surg 2016;64:1444-9.)
Clinical Relevance: Arterial grafts release growth factors, which can lead to myointimal hyperplasia formation and
atherosclerosis progression in the arterial tree. Both phenomena can cause graft occlusion. Inhibition of growth factor
release by arterial grafts can improve their clinical effectiveness.Myointimal hyperplasia (MH) and atherosclerosis pro-
gression are major obstacles to the clinical success of
arterial grafting.1 MH formation at the level of the anasto-
moses, and atherosclerosis progression in the distal arterial
tree, are more common in synthetic grafts than in autolo-
gous grafts.2-4 Clinical results in coronary artery bypass sur-
gery have shown that MH and atherosclerosis formation
are less common in arterial grafts like the internal mam-
mary artery than in the reversed saphenous veins.5,6 Several
growth factors have been implied in the genesis of MH in
the clinical and experimental setting.7-12
A series of animal experiments was performed to estab-
lish the correlation between MH formation and the biolog-
ical and physical characteristics of experimental arterial
grafts. MH is also a common clinical problem in transplan-
tation,13,14 and experiments were performed to compare
growth factors release in arterial autografts and allografts.
METHODS
Experimental design. We implanted 105 experimental
arterial grafts that were 1-cm long in the infrarenalthe Istituto Pietro Valdoni, University of Rome Sapienza.
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4abdominal aorta of Lewis rats (average weight, 250 g).
The same anastomotic technique was used in all animals: a
continuous suture was fashioned with starting points, at
180. We used 10-0 monofilament nylon sutures (Ethicon
Inc, New Jersey). Seven animals died in the early postoper-
ative period from occlusion of the graft, and they were
excluded from the study; 78 animals were humanely killed
4 weeks after surgery. All grafts were patent at the time of
the killing. Patency was tested opening the graft and
observing the inflow and outflow separately. Growth factor
release (platelet-derived growth factor [PDGF], basic fibro-
blast growth factor [bFGF], tumor necrosis factor [TNF]-a,
and interleukin (IL)-1) by the grafts was studied in organ
culture. This group of arterial grafts consisted of 15 synge-
neic arterial grafts, 15 syngeneic vein grafts, 30 polytetra-
fluoroethylene (PTFE) grafts (15 with normal compliance,
15 with reduced compliance), and 18 arterial allografts.
In 20 animals, PTFE grafts were inserted in the
abdominal aorta, and they were randomised to receive
either polyclonal antibody to bFGF (10 animals) or
nonspecific immunoglobulin (10 animals). Fourteen ani-
mals (seven animals in each group) were killed humanely
7 days after surgery, 24 hours after intraperitoneal injection
of bromodeoxyuridine (BrdU) to label proliferating
smooth muscle cells. The remaining six animals (three in
each group) were humanely killed 4 weeks after surgery
to determine the average thickness of the distal anasto-
motic site.
Type of anesthesia and operative procedures. The
animals were anesthetized with intramuscular xylazine
(3 mg/kg) and intramuscular ketamine (50 mg/kg), sup-
plemented with intraperitoneal ketamine for maintenance.
The same drugs were used at the time of the killing of the
JOURNAL OF VASCULAR SURGERY
Volume 64, Number 5 Sterpetti et al 1445animals. No heparin was used intraoperatively or postoper-
atively. No antiaggregant drugs were given to the animals.
Animal care complied with the Principles of Laboratory
Animal (National Institutes of Health publication 80.23,
revised 1996).
Vein grafts group. A 1-cm-long segment of supra
diaphragmatic inferior vena cava was obtained from donor
syngeneic Lewis rats, and it was transplanted in the
infrarenal abdominal aorta of syngeneic Lewis rats recipients.
PTFE grafts. A 1-cm-long segment of nonreinforced
PTFE graft (30 microns fibril length, 2 mm internal
diameter, 0.39 mm thick; W. L. Gore Associates Inc,
Flagstaff; Ariz) was inserted at the level of the abdominal
aorta in 15 animals. In another 15 animals a low-
compliance PTFE graft was inserted in a similar way at
the level of the abdominal aorta. The original PTFE graft
was wrapped with a rigid nylon sheet. The graft in a pre-
vious study showed a reduction in compliance of 50%.
Isogenic arterial grafts. A 1-cm-long segment of
abdominal aorta was obtained from donor syngeneic Lewis
rats, and it was transplanted in the infrarenal abdominal
aorta of a syngeneic Lewis rat recipient.
Allogenic arterial grafts. We used 18 Brown Norway
rats as donors of the abdominal aorta. This inbred strain of
rats was chosen for its immunologic incompatibility with
Lewis rats, which were used as recipients of the arterial
grafts. A 1-cm-long segment of abdominal aorta was ob-
tained from donor Brown Norway rats and transplanted in
the infrarenal abdominal aorta of Lewis rats.
Animal treated with anti-bFGF antibodies or
aspecific immunoglobulins. In 20 Lewis rats, a 1-cm-
long segment of PTFE graft was inserted at the level of
the abdominal aorta with the standard technique described.
In 10 animals, 0.5 mg of anti-bFGF-specific antibody (in a
1-mL solution) was injected intraperitoneally just after sur-
gery, and at 24 and 48 hours after the operation. In the
control group, nonspecific globulins were inoculated.
Fourteen animals (seven in each group) were humanely
killed 7 days after surgery. In all 14 animals, an intraperito-
neal injection of BrdU, at the dosage of 100 mg/kg, was
performed 24 hours before humane killing.
The remaining six animals (three in each group) were
humanely killed 4 weeks after surgery. At humane killing,
the carotid artery was cannulated and perfused with form-
aldehyde at a pressure of 100 mm Hg. The graft and the
aorta below and above the graft were excised to measure
the thickness of the aortic wall near the anastomoses.
Histology and histochemistry. Tissues (n ¼ 2 for
each group) were prepared analysis of the different growth
factors and of a-actin with frozen section techniques, as
previously described.2,13-15
Organ culture. The grafts and the control ungrafted
aortas and veins were opened longitudinally, and rinsed
thoroughly for 10 minutes with Dulbecco’s modified Ea-
gle’s medium supplemented with antibiotics (gentamycin
200 mg/mL, streptomycin 100 mg/mL, penicillin 100
IU/mL). The specimen were maintained for 5 days at
37C in a 5% CO2 atmosphere (n ¼ 12 for each group).The viability of the organ culture was assessed by incorpo-
ration of tritiated thymidine and by cytofluorometry.
Assay for mitogenic activity. Serum-free media
(20 mL) from grafts conditioned for 72 hours, and from
aortic conditioned media (n ¼ 12 for each group) were
added to Swiss 3T3 cells. The positive control group con-
sisted of Swiss 3T3 cells which received an equivalent vol-
ume of Dulbecco’s modified Eagle’s medium plus
recombinant growth factors (bFGF, PDGF, TNF-a, trans-
forming growth factor-b, IL-1; Boehringer Mannheim,
Germany). The negative control group received only
Dulbecco’s modified Eagle’s medium.
After 2 days, tritiated thymidine (0.5 mCi per well
plate) was added, and the serum cultures were incubated
for 18 hours and collected on Skatron filters (Skatron In-
struments, Sterling, Va) for radioactivity determination in
a scintillation counter (LKB Instruments Inc, Gaithers-
burg, Md).
Analysis of reduction of mitogenic activity by
antigrowth factor antibodies. Measurement of Swiss 3T3
cells DNA synthesis-stimulated activity of the conditioned
media from explanted grafts was repeated in presence of an
excess of monospoecific antibodies to bFGF (produced in
our laboratory; n ¼ 12 for each group), PDGF AA and BB,
transforming growth factor-b, TNF-a, and IL-1 (Genzyme
CO, Boston, Mass). Tritiated thymidine was again added,
and the cultures were incubated for 18 hours. After further
processing, the radioactivity was measured.
Assay of growth factors in the conditioned media.
The presence of growth factors in the conditioned media
was determined by inhibition antibody-binding assay, as
previously described (n ¼ 12 for each group).2,13-15 A
dilution of anti-bFGF mouse monoclonal antibody was
incubated with various dilutions of the grafts conditioned
media, in 400 mL/tubes precoated with phosphate-
buffered saline gelatine 2%. After 20 hours of incubation
at 4C, Staphylococcus aureus was added, and the immu-
noaggregate was removed by centrifugation. The residual
antibody-binding activity in the supernatant was measured
by enzyme-linked immunosorbent assay.2,15
BrdU labelling index. In animals treated with anti-
bodies to bFGF and control animals, an intraperitoneal in-
jection of BrdU at the dosage of 100 mg/kg, was
performed 24 hours before humane killing. Sections were
stained using anti-BrdU antibody (BU 33 Sigma St
Louis, Mo), diluted to 1:50. Antifactor VIII polyclonal
antibody, at a dilution of 1:300, to highlight endothelium,
and antimuscle actin antibody, diluted to1:100, to identify
smooth muscle cells, were used. The total number of
neointimal-labeled and unlabeled cells, in each high-power
field along the whole section length, was used as the BrdU-
labelling index. The BrdU-labeling index was assessed as
the mean percentage of neointimal smooth muscle-labeled
cells (labeled nuclei/total nuclei  100).
Statistical analysis. Data were expressed as mean
values 6 standard deviation. The c2 test, analysis of vari-
ance, and Student t-test were used where appropriate. Dif-
ferences were considered significant at the 5% critical level.
Fig 1. A, Histochemical localization of basic fibroblast growth factor (bFGF) in arterial vein grafts explanted 4 weeks
after surgery (transverse section): localization of bFGF in smooth muscle cells which form the area of myointimal
hyperplasia (MH; original magnification 400), L, Lumen. B, Histochemical localization of platelet-derived growth
factor (PDGF) in arterial vein grafts explanted 4 weeks after surgery (transverse section): localization of PDGF in
smooth muscle cells which form the area of MH (original magnification 400).
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Histology. PTFE grafts showed evidence of MH at
the level of the anastomoses. The midgraft portion was
covered by thrombin and fibrin. Vein grafts were
completely covered by endothelial cells. In the vein grafts,
the thickness of the intima-media layer was significantly
greater than that of ungrafted control veins (230 6 40 vs
50 6 20 microns; P < .01). Isogenic arterial grafts showed
only minimal evidence of MH, and the thickness of the
intima-media layer was similar to that of ungrafted arteries.
Allogenic arterial grafts showed evident signs of rejection,
with diffuse cellular infiltration in the adventitia. The
intima-media thickness was greater in allografts than in
isografts (250 6 30 vs 100 6 25 microns; P < .01).
Histochemistry. In vein grafts examined 4 weeks after
implantation in the arterial system, the area of MH was
positive for bFGF and PDGF (Fig 1, A and B). Lympho-
cytes heavily infiltrated the allografts, as demonstrated by
panleukocytes antibody, and they were found in all layers.
In allografts examined 4 weeks after implantation, the area
of MH was positive for IL-1 and TNF-a (Figs 2 and 3) but
not for PDGF and bFGF.
Growth factors and cytokine assay by enzyme-
linked immunosorbent assay. In PTFE grafts and vein
grafts, there was a significant release of PDGF and bFGF,
which led us to hypothesize that these two growth factors
were responsible for MH formation (Tables I and II). In
ungrafted veins and aortas, the production of PDGF and
bFGF was minimal (P < .01). Similarly, in arterial isogenic
grafts PDGF and bFGF release was minimal (P < .01).
PTFE grafts with decreased compliance had a greater
release of growth factors than PTFE with higher compli-
ance (P < .05) In arterial allografts, production of PDGF
and bFGF was minimal. There was a significant release of
IL-1 and TNF-a (P < .01).
Mitogenic activity of the conditioned media. Addi-
tion of serum-free conditioned media from PTFE, vein and
arterial allografts collected at 72 hours (n ¼ 12 for each
group) produced a significant increase of tritiated thymi-
dine uptake of Swiss 3T3 cell cultures, in comparison withconditioned media from control ungrafted veins, control
ungrafted aortas, and arterial isografts. These differences
were statistically significant (P < .01). The increased triti-
ated thymidine uptake (correlated with DNA synthesis and,
thus, with cell proliferation) was greater for conditioned
media from PTFE grafts, than for those from vein grafts
(P < .05).
Reduction of mitogenic activity by anti-bFGF and
anti-PDGF antibody in vitro. Addition of monospecific
anti-bFGF antibody to the medium of 3T3 cells cultures
exposed to conditioned media from PTFE and vein grafts
decreased the uptake of tritiated thymidine by 65% (P <
.001). Addition of monospecific anti-PDGF antibody to
the medium of 3T3 cells cultures exposed to conditioned
medium from PTFE and vein grafts decreased the uptake
of tritiated thymidine by 20% (P < .05). Addition of both
antibody to bFGF and anti-PDGF had only a minimal
effect on the tritiated thymidine uptake of 3T3 cells cul-
tures exposed to conditioned media from allografts.
BrdU labeling index. From the previous experiments,
bFGF seemed to have a fundamental role in the genesis
MH in vein and PTFE grafts. Polyclonal anti-bFGF anti-
body was used to inhibit the in vivo proliferative response
of smooth muscle cells after grafting. The labelling index
was decreased significantly (P < .01) in animals treated
with anti-bFGF in comparison with animals treated with
aspecific antibodies. The difference was evident at the level
of the proximal anastomosis, distal anastomosis, and the
PTFE graft. Four weeks after surgery, there was a signifi-
cant decrease in MH at the level of the distal anastomosis
of PTFE grafts in animals treated with anti-bFGF anti-
bodies compared with the control group (P < .05).
DISCUSSION
Several factors are responsible for MH formation in
arterial grafts, and an increased production of growth fac-
tors is probably the final biological mechanism leading to
smooth muscle cell proliferation.1-4,16-19 We found that
PTFE grafts produce a high quantity of PDGF and
bFGF, which can lead to anastomotic myointimal and
Fig 2. Histochemistry for interleukin (IL)-1 in arterial isografts (left) and arterial allografts (right) explanted 4 weeks
after surgery (transverse sections). No detectable localization of IL-1 in isografts (left). Evident localization of IL-1 in
the area of myointimal hyperplasia (MH) in aortic allografts (original magnification 200). L, Lumen.
Fig 3. Histochemistry for tumor necrosis factor (TNF)-a in arterial isografts (left) and arterial allografts (right)
explanted 4 weeks after surgery (transverse sections). No detectable localization of TNF-a in isografts (left). Evident
localization of TNF-a in the area of myoinitmal hyperplasia in aortic allografts (original magnification 200). L,
Lumen.
JOURNAL OF VASCULAR SURGERY
Volume 64, Number 5 Sterpetti et al 1447atherosclerosis progression in the distal arterial tree. The
source of these two growth factors is poorly defined. Plate-
lets, endothelial cells, and smooth muscle cells are able to
release PDGF and bFGF. Platelet deposition on synthetic
grafts is well-documented.18 In vitro studies suggest that
activated endothelial and smooth muscle cells produce a
high quantity of PDGF and bFGF. A similar activation of
endothelial and smooth muscle cells can be expected at
the level of the anastomoses for the initial surgical trauma
as well as for the mechanical stress caused by the different
elastic characteristics of the synthetic graft and of the host
artery.20 As initially showed by Abbott et al,21 grafts with
lesser compliance are at greater risk for occlusion. In our
study, PTFE grafts with reduced compliance produced a
greater quantity of growth factors.
The relationship between PDGF and bFGF and
myiontimal hyperplastic reaction in balloon traumatizedarteries has been studied in detail. The possibility to reduce
MH in this experimental setting with the administration of
antibodies to bFGF and PDGF has been shown in several
studies.8,9,22 In our study, antibodies to bFGF decreased
significantly the proliferation rate of smooth muscle cells
at the level of the anastomoses, with decreased formation
of anastomotic myoinitmal hyperplasia 4 weeks after graft
implantation. This finding demonstrated a direct causee
effect correlation between increased production of bFGF
and myointimal reaction. We tested only bFGF, which
was the growth factor released in greater quantities in the
PTFE grafts.
This evidence supports the theory that prevention of
anastomotic MH in synthetic grafts, should be based on
two main therapeutic approaches: (1) grafts with physical
characteristics similar to the host artery and (2) pharmaco-
logic intervention to reduce platelet deposition on the graft
Table I. Growth factor production (ng/cm2/72 hours)
PDGF AA PDGF BB bFGF
Arterial isografts 9 6 3 30 6 5 79 6 6
Vein grafts 7 6 2 62 6 6a 295 6 20b
PTFE (normal compliance) 28 6 4c 66 6 7c 404 6 22b
PTFE (low compliance) 32 6 4c 73 6 8c 455 6 20d
Arterial allografts 6 6 3 9 6 5 19 6 .02
Control ungrafted aorta 7 6 4 25 6 4 46 6 8
Control ungrafted vein 7 6 3 4 6 2 55 6 6
bFGF, Basic fibroblast growth factor; PDGF, platelet-derived growth factor;
PTFE, polytetrafluoroethylene.
aP < .95.
bP < .01.
cP < .05.
dP < .001.
Table II. Growth factor production (ng/cm2/72 hours)
IL-1 TNF-a
Arterial isografts 0.3 6 0.04 48 6 5
Vein grafts 0.2 6 0.04 50 6 6
PTFE (normal compliance) 0.3 6 0.02 49 6 6
PTFE (low compliance) 0.3 6 0.02 49 6 8
Arterial allografts 1.1 6 0.13a 500 6 45b
Control ungrafted aorta 0.16 6 0.02 60 6 7
Control ungrafted vein 0.17 6 0.02 65 6 8
IL, Interleukin; PTFE, polytetrafluoroethylene; TNF, tumor necrosis factor.
aP < .05.
bP < .001.
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block the action of PDGF and bFGF, either directly or
through their receptors. MH occurs in the wall of veins
implanted in the arterial circulation. This is a physiologic
adaptation of the vein to the new hydraulic system, with
high pressure and high wall shear stress. The increased
thickness of the vein is an adaptation that can prevent
vein rupture.23 In specific, traumatized segments, or near
the valves, the myohyperplastic reaction can go further
and can lead to stenosis and occlusion. In the clinical
setting, in coronary artery bypass surgery and in lower
limb arterial reconstruction, the saphenous vein undergoes
serious occlusive changes.24-27
In our study, veins grafted in the arterial circulation
produced a high quantity of PDGF and bFGF. This phe-
nomenon, which was not seen in isogenic arterial grafts,
could explain the clinical differences between venous and
arterial coronary grafts. These findings support the view
that pharmacologic intervention directed at decreasing
PDGF and bFGF production might be beneficial in pre-
venting occlusive changes in the wall. The biologic mech-
anisms leading to MH in arterial allografts seem different
from those at the basis of the same phenomenon in vein
and PTFE arterial grafts. Accelerated MH has emerged as
a major and life-threatening complication in long-term sur-
vivors of heart and kidney transplantation.13,14 In this
study, we found that aortic allografts of rats are heavily
infiltrated by lymphocytes that produce high quantities of
IL-1 and TNF-a. These molecules are powerful mitogensfor endothelial and smooth muscle cells. IL-1 and TNF-a
can initiate a cascade action of T-lymphocyte activation,
either directly or through expression of surface antigens
and, thus, promote local amplification by positive feed-
back.28 The nature of this positive feedback can explain
the rapidity with which MH forms in this setting.
Agents able to neutralize these cytokines and growth
factors either directly or through their receptors can be
beneficial in preventing MH, often seen after heart and
kidney transplantation.29-31 New and specific immunosup-
pressive treatments can decrease lymphocyte and macro-
phage infiltration of the transplanted artery, and prevent
growth factor production.
We conclude that agents able to reduce the release
of these growth factors or able to neutralize their ac-
tion, either directly or through blockage of their recep-
tors, may contribute to the prevention of MH. The
growth factors and cytokines are specific to each clinical
setting.
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Submitted Jun 3, 2015; accepted Jul 16, 2015.INVITED COMMENTARYRavi R. Rajani, MD, Atlanta, GaAlthough improvements in operative technique, adjunctive
maneuvers, local drug delivery, and systemic pharmacotherapy
have improved outcomes after arterial reconstruction, durable clin-
ical improvement continues to be limited by the development of
intimal hyperplasia and progressive native atherosclerosis. These
limitations have been successfully mitigated in the setting of coro-
nary artery bypass grafting because of the availability of an easily
accessible native arterial conduit. Unfortunately, no such native
conduit of sufficient length is readily usable for lower extremity
arterial bypass, and reversed vein conduits remain a marginally
acceptable substitute.
The authors here present a series of 105 aortic replacements in
rats, using a variety of available grafts. Postoperative growth factor
measurements were assessed, and the effect of conduit compliance
is also separately evaluated in an attempt to summarize the phar-
macologic and mechanical stressors felt to contribute to late graftfailure. Their findings highlight several of the important advances
made in bypass outcomes during the last 20 years: local pharmaco-
therapy to reduce early response to injury in vein grafts, local drug
delivery to improve patency after angioplasty, systemic pharmaco-
therapy to suppress midterm hyperplasia, and adjunctive anasto-
motic techniques in an attempt to mitigate compliance change
across an anastomosis.
As evidenced by the outcomes presented here, the basic mech-
anism by which hyperplasia progresses is clearly multifactorial and
also dependent on the type of conduit present. That a single silver
bullet solution will present itself remains unlikely; interventions
that are beneficial for vein grafts may not automatically improve
outcomes for prosthetic conduits. Rather, the postoperative man-
agement of these patients will likely continue to require graft-
specific maintenance therapy within the framework of broad scien-
tific guidelines.
